Roche introduces the navify brand for its digital health solutions at HLTH 2022

  • Roche unifies its digital health portfolio under the navify brand, providing a range of next-generation software solutions.
  • The navify portfolio uses digital solutions, analytics and data science to deliver insights that address real-world challenges in healthcare, enabling confident decision-making and leading to the delivery of personalized healthcare.
  • Navify digital solutions reinforce Roche’s commitment to helping providers and innovators connect with patients for better access, experience and care.

BASEL, Switzerland, November 4, 2022 /PRNewswire/ — Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today at the HLTH 2022 meeting in Las Vegas, NV, USA that its digital health portfolio will now be available under the navify® brand. navify digital solutions help providers and patients ‘navigate’ and ‘unravel’ a wide range of touchpoints by activating insights that provide evidence on how to optimize operational processes and clinical decision-making in health care. Health.

“Today we are using navify’s digital solutions such as algorithms and data science to deliver actionable information in healthcare, building on three decades of software experience with laboratory diagnostics,” said Moritz Hartmann, Head of Roche Information Solutions. “We are creating open digital ecosystems with labs, hospitals and medical technology companies to bring the latest innovations faster to society to better serve patients and help physicians deliver care to patients. These activities support our strategy to provide information that drives personalized attention.”

Together, navify brings new ways to:

  • Improving digital infrastructure interoperability: Today, limited capabilities to seamlessly connect and share data cost healthcare systems an estimated $30 billion in the US alone.1
  • Use advanced analytics to deliver operational excellence, improved workflows, and patient-centric ways of working—a global shortage of up to 15 million healthcare workers is projected by 2030:two providers are facing increasing workloads with fewer resources: finding additional efficiencies is a priority,
  • Generate advanced medical insights that increase clinical decision support: 2 out of 3 physicians are unsure whether they are overusing or underusing diagnostics, compared to their peers.3

Navify supports Roche’s 125-year commitment to providing pioneering science that helps healthcare organizations improve patient health by advancing medical knowledge, diagnosis and treatment. It also aligns with Roche’s 10-year ambition to build a leading and profitable knowledge business.

about browsing
Roche’s portfolio includes more than 30 digital solutions4 for laboratories, hospitals and patients around the world and many key initiatives to advance digital transformation in healthcare. Various late stage drivers5 with customers and technology partners are in place for digital infrastructure (navify Core Integrator), operational excellence (navify Sample Tracking), and medical insights (navify Screening for Cervical Cancer, navify Kidney Companion, and navify Algorithm Suite).

With browse Market, Roche connects healthcare providers and laboratories, third-party medical technology and other companies to help bring innovations to healthcare. Several startups or companies are involved and more are joining: Smart4Diagnostics, imito (, decide Clinical Software (glucotab), Glytec, Precordior (CardioSignal), SteadySense (SteadyTemp), Deigma, TestCard, Etheclo, Tracie Healthcare Solutions and Binary Technology Medial EarlySign, which develops AI-based clinical predictive analytics, is the latest to join, enabling EarlySign ColonFlag6 to be accessible to laboratories and hospitals through the Navify platform in the near future.

Information about Navify is available at

On Roche’s presence at HLTH 2022
James Musick, Global Head of Personalized Healthcare for Roche, will present on Tuesday, November 15 at 3:30 pm PT on the Seaport Stage. He will discuss how today’s convergence of pioneering science, technology and data is driving new patient-centric healthcare solutions that are unlocking sustainable and widespread access to personalized healthcare.

Featured navigation solutions on the Roche stand at HLTH 2022 include:

  • navigate Roche’s digital infrastructure solutions to securely integrate data into care environments and open digital ecosystems to accelerate innovation in care environments,
  • navify operational excellence solutions to drive efficiencies, increase health equity, and enable value-based care in labs and point-of-care (e.g., Viewics LabOps Suite, cobas infinity edge SMART, navify Sample Tracking manages samples sooner to reach the laboratories),
  • Navigate medical insight solutions using advanced analytics, algorithms to turn data into insights that increase clinicians’ ability to improve care (e.g., Navigate Oncology Portfolio, Navigate Diagnostic Optimization, Navigate Infection Management, Navigate the algorithm suite and Navigate Kidney Companion).

Roche’s presence at HLTH also includes 10 booth talks, such as:

  • Open digital ecosystem and the future of healthcare
  • Transforming healthcare together
  • navify oncology wallet
  • Innovative testing at the point of care

About Roche
Founded in 1896 in Basel, Switzerland, as one of the first industrial manufacturers of brand-name medicines, Roche has become the world’s largest biotechnology company and a world leader in in vitro diagnostics. The company pursues scientific excellence to discover and develop medicines and diagnostics to improve and save the lives of people around the world. We are pioneers in personalized health care and want to further transform the way health care is delivered to make an even bigger impact. To provide the best care for each person, we partner with many stakeholders and combine our strengths in Diagnostics and Pharmacy with data insights from clinical practice.

In recognition of our effort to take a long-term perspective in everything we do, Roche has been named one of the most sustainable companies in the pharmaceutical industry by the Dow Jones Sustainability Indices for the thirteenth consecutive year. This distinction also reflects our efforts to improve access to health care together with local partners in all the countries in which we work.

Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder of Chugai Pharmaceutical, Japan.

For more information please visit

All trademarks used or mentioned in this release are protected by law.



Fierce health. Health Technology – Industry Voices. [Internet; updated 2020, Aug 25; cited 2022, Sept2]. Available from:


World Health Organization. Health personnel [Internet; cited 2022, Sept 2]. Available from:


Sirovich BE, Woloshin S, Schwartz LM. Too little? too? Primary care physicians’ views on health care in the US: a brief report. Internal Medicine Archives. 2011 September 26; 171(17): 1582-5.


Current digital solutions under cobas® infinity or Viewics will transition to the navify brand over time, continuing to deliver the same value to healthcare organizations.


Some of these digital solutions are currently commercially available in select markets today.


In the US, the ColonFlag algorithm is marketed as the LGI-Flag™, as an indication for lower GI disorders.


Reference: Hammer, RD, Fowler, D., Sheets, LR, Siadimas, A., Guo, C., & Prime, MS, 2020. Digital tumor plating solutions have a significant impact on case preparation. JCO Clinical Cancer Informatics, 4, pp.757-768

For more information contact

Christine Englund, Director of Supplier Insights Communications, Roche Information Solutions
Telephone: +1 669 301 8709
Email: [email protected]

Monica Ryser, Head of Laboratory Information Communications, Roche Information Solutions
Telephone: +41 79 638 9492
Email: [email protected]

cision View original content to download media:


Company codes: OTC-BB:RHHBY, Switzerland:RO, OTC-PINK:RHHBY, Switzerland:ROG, OTC-QX:RHHBY

Leave a Comment